Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • History
    • Our Leadership
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Multiple Myeloma
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • What is Gene Therapy?
    • Gene Therapy Techniques
    • Clinical Trials
    • Our Pipeline
  • Our Products
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Corporate Presentation
  • Our Value Model
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Jenn Snyder

    VP, Corporate Communications

    (617) 448-0281

    JSnyder@bluebirdbio.com

  • Catherine Falcetti

    Senior Director, Corporate Communications

    (339) 499-9436

    CFalcetti@bluebirdbio.com

Investor Contacts

  • Ingrid Goldberg

    VP, Investor Relations

    (857) 217-0490

    IGoldberg@bluebirdbio.com

  • Elizabeth Pingpank

    Director, Investor Relations

    (617) 914-8736

    EPingpank@bluebirdbio.com

bluebird bio to Separate Oncology Business into Independent Company

  • Read more about bluebird bio to Separate Oncology Business into Independent Company

Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd Annual ASH Meeting

  • Read more about Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd Annual ASH Meeting

Long-Term Data for bluebird bio’s betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and β-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting

  • Read more about Long-Term Data for bluebird bio’s betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and β-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting

Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

  • Read more about Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

  • Read more about Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

  • Read more about bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

bluebird bio ASH Data Review Webcast

  • Read more about bluebird bio ASH Data Review Webcast

Barclays Gene Editing & Gene Therapy Summit

  • Read more about Barclays Gene Editing & Gene Therapy Summit

Cowen 2020 IO Next Summit

  • Read more about Cowen 2020 IO Next Summit

bluebird bio Announces November Investor Events

  • Read more about bluebird bio Announces November Investor Events

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Quick Links

  • Patients & Advocacy
  • Investors & Media
  • Careers
  • Contact Us

CONTACT INFO

info@bluebirdbio.com

clinicaltrials@bluebirdbio.com

investor@bluebirdbio.com

medinfo@bluebirdbio.com

Live - Terms & Privacy

  • Terms of Service
  • Privacy Policy
  • Cookie Notice
  • Sitemap
© 2021 bluebird bio, Inc. All Rights Reserved. Corp-GBL-00011 05/19

Live - Social Links